NASDAQ: QCLSQ/C Technologies Inc Stock
$5.67+1.60 (+39.31%)
Updated Jan 23, 2026
QCLS Price
$5.67
Fair Value Price
$6.67
Market Cap
$23.63M
52 Week Low
$2.50
52 Week High
$137.99
P/E
-0.05x
P/B
1.65x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.80M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.11
Operating Cash Flow
-$7M
Beta
1.22
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
QCLS Overview
Q/C Technologies, Inc. is focused on quantum-class photonic computing and blockchain infrastructure. The company has exclusive global rights to LightSolver's light-speed laser processing unit (LPU), a revolutionary light and laser-based computing system aimed at cryptocurrency vertical applications, reducing energy consumption by up to 90% while outperforming traditional GPUs and quantum computers.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine QCLS's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
QCLS
Ranked#316 of 487
Ranked#316 of 487
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $19.70 | A | |
| $6.79 | A | |
| $5.26 | A |
Be the first to know about important QCLS news, forecast changes, insider trades & much more!
QCLS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how QCLS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
QCLS ($5.67) is undervalued by 15.01% relative to our estimate of its Fair Value price of $6.67 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
QCLS ($5.67) is not significantly undervalued (15.01%) relative to our estimate of its Fair Value price of $6.67 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
QCLS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more QCLS due diligence checks available for Premium users.
Valuation
QCLS fair value
Fair Value of QCLS stock based on Discounted Cash Flow (DCF)
Price
$5.67
Fair Value
$6.67
Undervalued by
15.01%
QCLS ($5.67) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
QCLS ($5.67) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
QCLS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
QCLS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.05x
Industry
166.73x
Market
41.3x
QCLS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.65x
Industry
5.6x
QCLS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
QCLS's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.8M
Profit Margin
0%
QCLS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$37.2M
Liabilities
$15.9M
Debt to equity
1.11
QCLS's short-term assets ($11.15M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
QCLS's short-term assets ($11.15M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
QCLS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
QCLS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.2M
Investing
-$1.5M
Financing
$9.4M
QCLS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
QCLS vs Biotech Stocks
Q/C Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.